Intertek has announced a 6,000 sq ft expansion of its facility in Melbourn, UK to add laboratory space for characterization of large molecules for inhalation. In 2019, the company acquired a facility that doubled its total lab space in Melbourn to 40,000 sq ft at that time; the new expansion brings the total area to 46,000 sq ft.
The company, which sponsors an annual forum on inhaled and nasal biologics and DNA, cites increasing demand for services related to these products. The new lab space will include hazardous material handling capabilities and new instruments for advanced mass spectrometry and particle characterization, as well as bioassay and cell culture units.
Intertek Executive VP, Europe, Middle East and Africa and Government and Trade Services, Ross McCluskey commented, “This GMP lab expansion significantly enhances Intertek’s testing and analytical capabilities, enabling our clients developing novel inhaled biologics to accelerate their drug development timelines and ensure the highest standards of quality and efficacy in their products.”
Intertek Pharmaceutical Services Director, UK, and Switzerland, Ashleigh Wake said, “Our growing facility underscores our dedication to supporting innovation and the continuous development of safe and effective inhaled biologics. In partnership with our clients, we are helping to advance innovations in critical medicines that will reach patients in need worldwide.”
Read the Intertek press release
